156 related articles for article (PubMed ID: 17051958)
21. A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma.
Khaled HM; Hamza MR; Mansour O; Gaafar R; Zaghloul MS
Eur J Cancer; 2000 Jul; 36 Suppl 2():34-7. PubMed ID: 10908847
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
[TBL] [Abstract][Full Text] [Related]
23. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Li J; Juliar B; Yiannoutsos C; Ansari R; Fox E; Fisch MJ; Einhorn LH; Sweeney CJ
J Clin Oncol; 2005 Feb; 23(6):1185-91. PubMed ID: 15718315
[TBL] [Abstract][Full Text] [Related]
24. A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
Tinker A; Winquist E; Canil C; Moore M; Murray RN; Chi KN
Am J Clin Oncol; 2006 Feb; 29(1):3-7. PubMed ID: 16462494
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
Song YS; Cho JS; Cho KS; Doo SH; Chung BH; Kim SJ; Yang WJ; Song KH; Kim CI; Hong SJ
Urol Int; 2010; 85(1):47-51. PubMed ID: 20234122
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?
Als AB; Sengelov L; Von Der Maase H
Acta Oncol; 2008; 47(1):110-9. PubMed ID: 17851853
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine and cisplatin for advanced, metastatic bladder cancer.
Cohen MH; Rothmann M
J Clin Oncol; 2001 Feb; 19(4):1229-31. PubMed ID: 11181690
[No Abstract] [Full Text] [Related]
29. [First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced or metastatic urothelial cell carcinoma (JASINT-1 - AB 38/11) of AUO].
Rexer H
Urologe A; 2011 Aug; 50(8):974-6. PubMed ID: 21779884
[No Abstract] [Full Text] [Related]
30. Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer.
von der Maase H
Eur J Cancer; 2000 Jul; 36 Suppl 2():13-6. PubMed ID: 10908843
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
Caffo O; Fellin G; Graffer U; Valduga F; Bolner A; Luciani L; Tomio L; Galligioni E
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1310-6. PubMed ID: 14630267
[TBL] [Abstract][Full Text] [Related]
33. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
34. [First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427 - AB 39/11 of the Working Group Urological Oncology)].
Rexer H
Urologe A; 2011 Dec; 50(12):1617-8. PubMed ID: 22159705
[No Abstract] [Full Text] [Related]
35. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.
Stadler WM; Hayden A; von der Maase H; Roychowdhury D; Dogliotti L; Seymour L; Kaufmann D; Moore M
Urol Oncol; 2002; 7(4):153-7. PubMed ID: 12474531
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
[TBL] [Abstract][Full Text] [Related]
37. Lymphoepithelioma-Like Bladder Carcinoma: A Diagnostic and Therapeutic Challenge. Contribution Using a New Case and Review of the Literature.
Rodríguez-Cabello MA; Méndez-Rubio S; Sanz-Miguelañez JL; Saenz-Medina J; Garrido-Abad P; Del-Barrio-Díaz-Aldagalan A; López-Elzaurdia C; Platas-Sancho A
Clin Genitourin Cancer; 2017 Jun; 15(3):e507-e515. PubMed ID: 28139445
[No Abstract] [Full Text] [Related]
38. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
Jin JO; Lehmann J; Taxy J; Huo D; Stöckle M; Vogelzang NJ; Steinberg G; Stadler WM
Clin Genitourin Cancer; 2006 Sep; 5(2):150-4. PubMed ID: 17026804
[TBL] [Abstract][Full Text] [Related]
40. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
